Biocon
companyActive threads
Biocon targets mid-20% margins as biosimilars grow
3 Min Read (Photo Credit : AI generated ) Biocon expects double-digit revenue growth in its biosimilars business to continue, with margins targeted at the mid-20% range and expected to improve further, the biopharmaceutical company told CNBC-TV18. Management said its target of reaching $1 billion in biosimilars revenue was a matter of when, rather than if, as the company expands its portfolio across markets.
Biocon wins 10-year Brazil Pertuzumab deal, shares rise 2%
Biocon has secured a 10-year supply contract with a Brazilian partner for its breast cancer biosimilar Pertuzumab, driving a 2% share gain. The company's CEO also signaled that biosimilars could soon reach $1 billion in revenue, citing strong insulin demand. This deal marks a strategic expansion in Latin America and reinforces Biocon's growing biosimilar portfolio.
Biocon gets USFDA approval for Yesintek autoinjector
According to a regulatory filing by the company on the BSE, the Yesintek single-dose prefilled autoinjector offers patients with another important treatment option. This new delivery format supports more tailored treatment approaches across different care settings and patient needs.
Biocon gets US FDA nod for Yesintek autoinjector
Biocon gets supplemental US FDA nod for Yesintek prefilled autoinjector Biocon said that its US subsidiary has received supplemental U.S. Food and Drug Administration (FDA) approval for Yesintek (ustekinumab-kfce) single-dose prefilled autoinjector in various strengths. Yesintek was originally approved by the U.S.
Biocon profits surge over four-fold
2 Min Read Biocon reported a more than four-fold jump in consolidated net profit for the June quarter on Wednesday, August 5, as its biopharmaceutical business and lower finance costs grew, even as its services business remained under pressure. The biopharmaceutical company posted a consolidated net profit of ₹141 crore for the June quarter, compared with ₹31.4 crore in the year-ago period. Revenue from operations rose 10% year-on-year to ₹4,336 crore from ₹3,942 crore.
Intelligence feed· 3 articles in 1440m
Biocon CEO says biosimilars can reach $1 billion revenue soon, insulin demand strong - CNBC TV18
New: Biocon CEO says biosimilars can reach $1 billion revenue soon, insulin demand strong - CNBC TV18
Biocon shares gain after bagging 10-year contract in Brazil for Breast Cancer treatment drug - CNBC TV18
Story first reported.
Biocon sees double-digit biosimilars growth continuing, targets mid-20% margins - CNBC TV18
Story first reported.